慢性丁型肝炎患者报告结局:bulevirtide III期MYR301试验的探索性分析
本研究为开放标签随机III期试验的探索性分析,纳入150例慢性丁型肝炎且代偿期肝病患者,按1:1:1随机分为对照组、bulevirtide 2 mg/日组和10 mg/日组治疗48周。结果显示,2 mg组在肝炎特异性生活质量问卷的生理角色、肝炎特异性限制和肝炎特异性健康困扰领域较对照组有显著改善;48周时2 mg组EQ-5D-3L视觉模拟量表健康状态较基线的平均改善大于对照组。作者认为bulevirtide单药治疗48周可能改善患者的部分健康相关生活质量。
要点
- 2 mg bulevirtide组在肝炎生活质量问卷的生理角色、肝炎特异性限制和健康困扰领域较对照组显著改善。
- 48周时2 mg组EQ-5D-3L视觉模拟量表健康状态较基线的平均改善大于对照组。
- 疲劳严重程度量表评分在各治疗组间保持稳定。
核心结论
- 患者报告结局提示,bulevirtide单药治疗48周可能改善慢性丁型肝炎患者的部分健康相关生活质量。
研究设计与样本
- 开放标签、随机、III期试验的探索性分析,纳入150例慢性丁型肝炎且代偿期肝病患者。
- 患者按肝硬化状态分层,按1:1:1随机分为对照组、bulevirtide 2 mg/日组或bulevirtide 10 mg/日组,治疗48周。
- 在基线、24周和48周使用EQ-5D-3L、肝炎生活质量问卷和疲劳严重程度量表评估健康相关生活质量。
主要发现
- 基线时治疗组(2 mg组n=49;10 mg组n=50)与对照组(n=51)的患者特征和健康相关生活质量评分均衡。
- 2 mg bulevirtide组在肝炎生活质量问卷的生理角色、肝炎特异性限制和肝炎特异性健康困扰领域较对照组有显著改善。
- 肝硬化患者中接受bulevirtide者较对照组在一般健康、肝炎特异性限制和肝炎特异性健康困扰领域报告数值更高的评分。
- 疲劳严重程度量表评分在各治疗组间全程保持稳定。
- 48周时2 mg组EQ-5D-3L视觉模拟量表健康状态较基线的平均改善大于对照组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Once-daily treatment of chronic hepatitis delta (CHD) with bulevirtide is well tolerated and associated with significant reductions in HDV RNA in the blood and in biochemical liver disease activity. This study explored the effects of 48-week bulevirtide treatment on health-related quality of life (HRQoL) in patients with CHD. METHODS: In an open-label, randomised, phase III trial, 150 patients with CHD and compensated liver disease were stratified by cirrhosis status and randomised 1:1:1 to no treatment (control), bulevirtide 2 mg/day, or bulevirtide 10 mg/day for 48 weeks. HRQoL was evaluated by the following patient-reported outcome instruments at baseline, 24 weeks, and 48 weeks: EQ-5D-3L, Hepatitis Quality of Life Questionnaire, and Fatigue Severity Scale. RESULTS: Patient characteristics and HRQoL scores were balanced at baseline between the treatment (2 mg, n = 49; 10 mg, n = 50) and control (n = 51) groups. Patients receiving 2 mg bulevirtide reported significant improvements compared with controls on the Hepatitis Quality of Life Questionnaire domains of role physical, hepatitis-specific limitations, and hepatitis-specific health distress. Numerically higher scores for general health, hepatitis-specific limitations, and hepatitis-specific health distress domains were reported by patients with cirrhosis who received bulevirtide vs. controls. Fatigue Severity Scale scores remained stable across treatment groups throughout. At week 48, patients in the 2 mg group showed greater mean improvement from baseline in health status compared with controls on the EQ-5D-3L visual analogue scale. CONCLUSION: Patient-reported outcomes indicate that 48-week treatment with bulevirtide monotherapy may improve aspects of HRQoL in patients with CHD. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier, NCT03852719. IMPACT AND IMPLICATIONS: Bulevirtide 2 mg is the only approved treatment for patients with chronic hepatitis delta (CHD) in the EU. Patients with CHD have worse quality of life scores than those with chronic hepatitis B. Bulevirtide treatment for 48 weeks reduced HDV RNA and alanine aminotransferase levels and was well tolerated among patients with CHD. For the first time, this study shows that patients who received bulevirtide therapy for 48 weeks reported improvements in physical and hepatitis-related quality of life domains compared with those who did not receive therapy (control group).
引用
- Buti M, Wedemeyer H, Aleman S, et al. Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide. J Hepatol. 2024. PMID: 39009085. doi:10.1016/j.jhep.2024.06.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。